The United States Food and Drug Administration (FDA) has granted United States-based Global Blood Therapeutics (GBT) Inc accelerated approval for Oxbryta (voxelotor) tablets intended for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older, it was reported yesterday.
The product is an oral therapy taken once daily and is the first approved treatment that directly inhibits sickle haemoglobin polymerisation, the root cause of SCD. It is likely to be offered through GBT's specialty pharmacy partner network within two weeks.
The accelerated approval of the product is reportedly based on clinically meaningful and statistically significant improvements in haemoglobin levels, accompanied by decrease in red blood cell destruction (hemolysis). Data from the Phase three HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErisation) Study of 274 patients 12 years of age and older with SCD indicated that, after 24 weeks of treatment, 51.1% of patients receiving Oxbryta achieved a greater than 1g/dL increase in haemoglobin compared with 6.5% receiving placebo (p
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML